Pfizer’s vaccine trial data holds up in the real world, according to large-scale study in Israel

A clinical trial conducted last fall proved a vaccine developed by Pfizer and BioNTech. It is 95% effective in preventing the symptoms of COVID-19.

After that and other vaccines were widely used, the question remained whether they would work as well.

A new study of more than 500,000 people vaccinated in Israel strongly suggests that the answer is yes.

A study published Wednesday in The New England Journal of Medicine found that people who received the Pfizer-BioNTech vaccine were 94% less likely to get sick than those who did not. They also had much lower mortality, hospitalization, and infection rates-among those who were tested for the virus.

Josh Mishaw, a global health expert at the Kaiser Family Foundation who was not involved in the study, called it an “important milestone.”

“In the past, we had to rely on scattered small reports and unpeer-reviewed discoveries to get a glimpse of how effective the COVID-19 vaccine is in the real world,” he said. It was.

This study did not address the critical question of whether vaccination would prevent viral infections in humans.

Clinical trials of various vaccines have focused on whether participants have developed symptoms, leaving the possibility of infecting people who are protected from the disease and unknowingly infecting others. ..

The new study did not systematically test for the virus, so there was no way to measure how many asymptomatic people were infected.

However, among those tested because they wanted to make sure they were sick or not infected, those who received both vaccines were more likely to get a positive result than members of the control group92. It was% low. It was not vaccinated.

Dr. Noam Barda, one of the authors, said research is currently underway to rigorously test vaccinated people to determine whether vaccination prevents infection and infection. ..

Dr. Carlos del Rio, an infectious disease researcher at Emory University who was not involved in the study so far, said it was “extremely” to see highly effective data carried over from clinical trials to the real world. Is encouraging. “

Controlled clinical trials are the best way to test the effectiveness of new vaccines, but they are far from a complete prediction of how deployment will proceed-especially very urgent and challenging. I will.

Vaccinated people may not follow the banned timeline for taking shots. Vaccines should be transported over long distances and kept cold. Many things go wrong and can be detrimental.

The new study used data from 596,618 people who received the Pfizer-BioNTech vaccine between December 20th and February 1st. Another 596,618 unvaccinated people were selected for control based on age, gender, neighborhood, pre-existing condition, and so on. Factors that can affect your chances of getting a virus or getting sick.

All participants were members of Clalit Health Services, Israel’s largest medical institution.

Even after just one dose, the vaccinated group performed much better than the unvaccinated companion. They were 57% less likely to get sick and 74% less likely to be hospitalized. After the second and last dose, these numbers increased to 94% and 87%.

Two to three weeks after the first injection, the vaccine was 72% effective in preventing death.

Jennifer Nuzzo, an epidemiologist at the Johns Hopkins Bloomberg School of Public Health, said the findings “should give great hope that vaccines can be used to prevent hospitalization and death and effectively protect against the virus.” ..

The vaccine worked equally well in all age groups.

Nicholas Davis, an epidemiologist at the London School of Economics and Tropical Medicine who was not involved in the study, said he had a high degree of protection for the elderly and people with multiple chronic health problems. He said the protection against was slightly lower. We are optimistic about the effectiveness of the vaccine in the most vulnerable populations. “

The authors of the study also said that the emergence of coronavirus variants did not appear to have a significant impact on vaccine efficacy.

Clinical trials were conducted when most of the viruses in circulation were in close agreement with those used in the design of the Pfizer-BioNTech vaccine. The new study did not examine the most common variants among participants, but B.1.1.7 (the so-called UK variant) accounted for the majority of all Israeli cases by the end of the study period. It was.

Israel far outperforms most other countries in vaccination campaigns, with more than half of its population vaccinated.

Pfizer’s vaccine trial data holds up in the real world, according to large-scale study in Israel Source link Pfizer’s vaccine trial data holds up in the real world, according to large-scale study in Israel

Related Articles

Back to top button